Paper of the Month - February, 2011

0 rating

Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized Phase III trial GOELAMS-LTP95.



READER POLL

L&L poll 2
What do you consider to be the most exciting advances in therapeutics research in myeloid leukemia at present?






Powered by NetPolls

WEB LINKS

SUBMIT AN ARTICLE